Roche’s fenebrutinib shows unprecedented positive phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis ...
Happy Tuesday! SoftBanks Sumer Juneja discussed the funds India strategy, Lenskarts public listing, and more in an exclusive ...
The demand for experienced professionals is far outpacing supply, with firms aggressively poaching from banks, brokerages and ...
[11:01 am] ASX 200 currently 0.25% higher, trading around the midpoint of today's intraday range (+0.45% and -0.06%). Strong ...
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at ABOUT TG THERAPEUTICS TG Therapeutics is a fully ...
Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears ...
A legal fight over Springfield’s attempt to stop residents from recording public council meetings appears to have stalled, as ...
GovHost, a leading provider of public safety software solutions, today announced its acquisition of True North Software LLC, an Illinois-based company known for its cloud-native Computer-Aided ...
Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...
lovemoney.com on MSN
Exploring the fates of Titanic's richest passengers
From America's richest man to one of the world's first film stars, some of the world’s richest people were lost to the waves, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback